178 related articles for article (PubMed ID: 23974721)
21. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.
Sarvi S; Mackinnon AC; Avlonitis N; Bradley M; Rintoul RC; Rassl DM; Wang W; Forbes SJ; Gregory CD; Sethi T
Cancer Res; 2014 Mar; 74(5):1554-65. PubMed ID: 24436149
[TBL] [Abstract][Full Text] [Related]
22. G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133⁺ cancer stem-like cells in hepatocellular carcinoma.
Yan M; Li H; Zhu M; Zhao F; Zhang L; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
PLoS One; 2013; 8(4):e61056. PubMed ID: 23593389
[TBL] [Abstract][Full Text] [Related]
23. [The CD133 polyclonal antibody generation and cancer stem cells identification].
Tian JL; Cai PL; Xia XQ; Li FH; Wang DH; Chen MN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):422-6. PubMed ID: 21827013
[TBL] [Abstract][Full Text] [Related]
24. Targeting cancer stem cells through L1CAM suppresses glioma growth.
Bao S; Wu Q; Li Z; Sathornsumetee S; Wang H; McLendon RE; Hjelmeland AB; Rich JN
Cancer Res; 2008 Aug; 68(15):6043-8. PubMed ID: 18676824
[TBL] [Abstract][Full Text] [Related]
25. Patient derived cell culture and isolation of CD133⁺ putative cancer stem cells from melanoma.
Welte Y; Davies C; Schäfer R; Regenbrecht CR
J Vis Exp; 2013 Mar; (73):e50200. PubMed ID: 23525090
[TBL] [Abstract][Full Text] [Related]
26. Basic studies on radioimmunotargeting of CD133-positive HCT116 cancer stem cells.
Jin ZH; Sogawa C; Furukawa T; Saito Y; Aung W; Fujibayashi Y; Saga T
Mol Imaging; 2012; 11(6):445-50. PubMed ID: 23084245
[TBL] [Abstract][Full Text] [Related]
27. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer.
Xiang T; Long H; He L; Han X; Lin K; Liang Z; Zhuo W; Xie R; Zhu B
Oncogene; 2015 Jan; 34(2):165-76. PubMed ID: 24362529
[TBL] [Abstract][Full Text] [Related]
29. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ
Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635
[TBL] [Abstract][Full Text] [Related]
30. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody.
Wang CH; Chiou SH; Chou CP; Chen YC; Huang YJ; Peng CA
Nanomedicine; 2011 Feb; 7(1):69-79. PubMed ID: 20620237
[TBL] [Abstract][Full Text] [Related]
31. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
32. IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation.
Chen Y; Zhang F; Tsai Y; Yang X; Yang L; Duan S; Wang X; Keng P; Lee SO
Radiat Oncol; 2015 Nov; 10():227. PubMed ID: 26572130
[TBL] [Abstract][Full Text] [Related]
33. Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties.
Bostad M; Berg K; Høgset A; Skarpen E; Stenmark H; Selbo PK
J Control Release; 2013 Jun; 168(3):317-26. PubMed ID: 23567040
[TBL] [Abstract][Full Text] [Related]
34. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells.
Yang Q; Zhang T; Wang C; Jiao J; Li J; Deng Y
Eur J Pharm Biopharm; 2014 Nov; 88(3):737-45. PubMed ID: 25460146
[TBL] [Abstract][Full Text] [Related]
35. Combination use of anti-CD133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity.
Moriwaki K; Okudo K; Haraguchi N; Takeishi S; Sawaki H; Narimatsu H; Tanemura M; Ishii H; Mori M; Miyoshi E
Cancer Sci; 2011 Jun; 102(6):1164-70. PubMed ID: 21392166
[TBL] [Abstract][Full Text] [Related]
36. CD133-targeted niche-dependent therapy in cancer: a multipronged approach.
Mak AB; Schnegg C; Lai CY; Ghosh S; Yang MH; Moffat J; Hsu MY
Am J Pathol; 2014 May; 184(5):1256-62. PubMed ID: 24589338
[TBL] [Abstract][Full Text] [Related]
37. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype.
Ames E; Canter RJ; Grossenbacher SK; Mac S; Chen M; Smith RC; Hagino T; Perez-Cunningham J; Sckisel GD; Urayama S; Monjazeb AM; Fragoso RC; Sayers TJ; Murphy WJ
J Immunol; 2015 Oct; 195(8):4010-9. PubMed ID: 26363055
[TBL] [Abstract][Full Text] [Related]
38.
Lin TC
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326089
[TBL] [Abstract][Full Text] [Related]
39. Selective lentiviral gene delivery to CD133-expressing human glioblastoma stem cells.
Bayin NS; Modrek AS; Dietrich A; Lebowitz J; Abel T; Song HR; Schober M; Zagzag D; Buchholz CJ; Chao MV; Placantonakis DG
PLoS One; 2014; 9(12):e116114. PubMed ID: 25541984
[TBL] [Abstract][Full Text] [Related]
40. Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells.
Coffman L; Mooney C; Lim J; Bai S; Silva I; Gong Y; Yang K; Buckanovich RJ
Cancer Biol Ther; 2013 Feb; 14(2):184-92. PubMed ID: 23192269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
